Market Overview

UPDATE: Morgan Stanley Reiterates on Allscripts Healthcare Solutions as Momentum will Continue in 2014

Share:
Related MDRX
Jefferies: 10 Buyout Targets To Own During The M&A Boom
Stifel Sees 'Limited Growth Opportunities' For Allscripts

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and raised the price target from $20.00 to $21.00.

In the report, Morgan Stanley noted, “Allscripts is a diversified HCIT vendor for hospitals, physician practices, and other healthcare providers. New leadership has solidified the existing customer base with increased product quality, investment in R&D, and product roadmap. Leadership position in growing area of Population Health through strategic acquisition of dbMotion. Replacement of EHR systems ahead of Meaningful Use Stage 2 provides an opportunity from both legacy MDRX and implementation of dbMotion. Compelling valuation – trades at a steep discount to HCIT peers.”

Allscripts Healthcare Solutions closed on Thursday at $17.22.

Latest Ratings for MDRX

DateFirmActionFromTo
Apr 2015Stifel NicolausInitiates Coverage onHold
Mar 2015RW BairdInitiates Coverage onOutperform
Feb 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDRX)

Around the Web, We're Loving...